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out among our patients. Before being allocated into the study 
groups, the patients had undergone a course of dental treatment 
programs for three weeks in order to reduce the amount of super- 
imposed ental inflammation as mnch as possible. Thereafter, the 
patients were randomized into intervention and control groups. 
Metronidazole tablets 250 mg/TDS were given to the interven- 
tion group, while the control group received the same amount of 
placebo. Patients were examined by a blinded periodontologist, at 
clays 0, 7, 14, and 2 I, to determine the gingival overgrowth scores, 
Results: The two groups were identical in age, gender, cause of 
receiving cyclosporine (kidney or bone marrow transplantation), 
duration of receiving cyclosporine, plasma level of cyclosporine 
and gingival overgrowth scores. Gingival enlargement improved 
in 7 patients, of whom 6 were in our intervention group (54.5%). 
The response to reatment was different in two groups ignificant- 
ly (P= 0.03). No association was found between gender, cause of 
receiving cyclosporine, duration of receiving cyelosporine, plasma 
level of cyclosporine and gingival overgrowth scores variables and 
response to treatment. Conclusion: In conclusion, our findings 
suggest hat we can benefit the advantages of metronidazole 
administration i  CIGH. Mthough we think that higher doses of 
metronidazole in association with oral hygiene programs and den- 
tal treatment planning could show better esults in such patients. 
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RECOVERY OF LEUKOCYTES FROM CORD BLOOD UNITS AFTER CON- 
TROLLED RATE FREEZE IN DMSO AND CRYOPRESERVATION IN THE 
VAPOR PHASE OF LIQUID NITROGEN 
Latze, T.A.t; Buenviaje, J / ;  Phmkett, M/; Law, lO.2 1. Americmz Red 
C'ross fVestetvz Area Commu~ity Cord Blood Ba*zk, Pot'tla~M, OR; 
2. University of Califor*zia, Sa~z Diego, &'hool of 3iedieiTze, La ffolla, CA. 
American Red Cross, Western Area Community Cord Blood 
Bank has established a program to assure the quality of cryopre- 
served volunteer donor cord blood units (CBU). Recovery. (Rec) 
of leukocytes (WBC) and WBC viability after CBU thawing are 
important surrogate measures CBU quality. We determined tl~e 
Rec of WBC in cryopreserved CBU immediately post-thaw and 
after dilution and washing in Dextran 40/5% Albumin (D/A), 
which is widely employed. Methods: CBU were collected from 
consented volunteer donors. CBU that were eligible for trans- 
plant, but had less WBC than required by storage criteria (6 ES) 
were studied. CBU were processed within 48 hours by Rubin- 
stein's method. The CBU volume after addition of 10% DMSO 
was 25 ml. CBU were cryopreserved by controlled rate freezing 
and stored in vapor phase liquid nitrogen for up to I year. Twelve 
CBU selected for study were removed from storage and immedi- 
ately placed in a 37 C waterbath. After thawing, the CBU was 
maintained at 4 C and a sample was immediately removed to 
assess post-thaw WBC (% NC-Rec) and cell viability by Trypan 
blue dye exclusion (% TB-viable). The CBU was diluted over 2 
rain in 25 ml D/A, samples removed, then the CBU was diluted to 
100 ml in D/A. The CBU was centrifuged at 400 xG at 4 C and 
resuspended in 25 ml of D/A. WBC Rec and NC viability were 
assessed post-thaw, after the 1:1 dilution in D/A, and post wash 
and resuspension. I  separate experiments, the Rec of CD34-bear- 
ing cells was measured. Results: There was a median 22% loss of 
NC after thawing, and additional NC loss after dilution and wash 
ing. Post thaw trypan blue dye viability was slightly reduced. In 6 
separate xperiments he Rec of CD34+ cells was 107 + 31% after 
thawing and 106 -+ 33 after washing. Conclusions: Thawing of 
cryopreserved CBU was associatedwith loss of approximately 
22% of the total NC and reduction in overall cell viability. Fur- 
ther cell loss accompanied washing. Recovery of CD34 bearing 
cells was uperior to total NC. Hematopoietic progenitor growth 
in culture after CBU thawing was consistent with the above. 
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EX VIVO ENGINEERING OF PREVIOUSLY THAWED AND CRYOPRE- 
SERVED UMBILICAL CORD BLOOD (UCB) WITH INTERLEUKIN (IL)-2, 
IL-7, IL-12 AND ANTI-CD3 FOR EXPANSION OF CYTOTOXIC T LYM- 
PHOCYTES (CTL): PROMISING STRATEGY FOR ADOPTIVE CELLULAR 
IMMUNOTHERAPY (ACI) POST UCB TRANSPLANTATION(T) 
Cairo, M.S.; Ayello, J.; vat~ de Ven, C. Child'ren's Hospital ofNew 
York Presbyteriml, New York, NY. 
Limitations associated with using UCB as a source for ACI post 
UCBT includes the lack of donor immunoeffector cells from the 
original cryopreserved UCB unit and/or immaturity of CB cellular 
immunity. We have demonstrated that CTL can be selectively 
engineered and activated from fresh and cryopreserved and thawed 
(CT) aliquots of UCB (Robinson/Cairo et al, Exp Hem 30:245, 
2002). In this study we evaluated and compared the activation and 
NK and LAK cytotoxicity of UCB CTL  Thawed UCB aliquots 
were monocyte depleted (5 xl06 cells/ml) in serum-free (SF) AIM- 
V in 5% CO2 @ 37°C. Nonadherent cells (lxl06 cells/ml) were 
either cultured in SF AIM-V + anti-CD3 (50 ng/ml), IL-2 (5 
ng/ml), IL-7 (10 ng/ml) and IL-12 (10 ng/ml) (AB/CY) or in SF 
AIM-V alone for 48 hours @ 37°C in 5% CO2 or expanded, recry- 
opreserved and rethawed (TECT), or not expanded but recryopre- 
served, rethawed and subsequently expanded (TCTE). NK subsets 
were analyzed by flow cytometry and NK and LAK cytotoxicity by 
YVST- 1 methodology utilizing a 10:1 E:T ratio against K562 (NK) 
and Dandi (LAK), respectively. A significant enhancement i  NK 
cytotoxicity was seen when UCB cells were cultured in the AB/CY 
cocktail (p<0.001) when compared to media alone, but no differ- 
ence between the nrodalities (TE: 0.73+0.03 vs 0.16-+0.01; 
TECT:0.72_+0.03 vs 0.16+_0.01 and TCTE:  0.75+0.04 vs 
0.16-+0.01). Similarly, there was significant enhancement of LAK 
cytotoxcity with all modalities of AB/CY stimulation vs media 
alone (p<0.001) but no difference between modality (TE: 0.39-+0.01 
vs 0.26-+0.0l; TECT: 0.37-+0.008 vs0.23+_0.002; TCTE: 0.41_+0.01 
vs 0.20-+0.01). Furthermore, there was a signfificant increase in the 
CD3-/16+/56+ subset of TE, TECT and TCTE when compared 
to media alone (TE: 60.2-+1.24% vs 47.33-+0.55%, n=3, p<0.001; 
TECT:  60.67+2.4% vs 46.68-+1.3%, n=3, p<0.001; TCTE:  
60.7+-3.27% vs 45.45_+1.4%, n=3, p<0.001). These data suggest that 
previously cryopreserved an  thawed UCB aliquots may be engi- 
neered at time of UCB transplant, ex vivo expanded and activated 
for cytotofic (NK & LAK) potential and recryopreserved for later 
use for DLI post UCBT. Xenotransplant animal studies are under- 
way to examine the in vivo effects of this UCB CTL population. 
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ONCE AND TWICE FILGRASTIM FOR ALLOGENEIC PBSC MOBILIZATION 
Yuji, I(.1; Hamaki, T.e; Iiji~la, K. 2, Yosihcma, S.2; Imataki, 0.2; Koji- 
ma, R.2; Ueymna, j.2; ~smni, E.e; Mmo, F.2; JliitaJd, 1(.2; Mori, S. e 
1. ToT:a*mmon Hospital, Minato-ku TOI~O, Japing; 2. Japa,z Hema- 
tology and 07~cology Clinical Study Group, Bu,~kyo-ku TOIxTO, ffapan. 
Objective: To compare fficacy and safety in allogeneic periph- 
eral blood stem cell (PBSC) donors who received 400gg/m^2/day 
of filgrastim administered sl~bcutaneously once daily (Once-daily 
regimen) or in two-divided ose every 12 hours (Twice-daily regi- 
men). Design: An open-label, randomized, multicenter phase III 
trial. Patients: Between May 2001 and May 2002, 72 PBSC 
donors were enrolled in this study. Eligibility criteria was as fol- 
lows: Allogeneic PBSC donors to related patients aged between 16 
and 65 years, eligible for the criteria described in the Japan Soci- 
ety for Hematopoietic Cell Transplantation (JSHCI) guideline of 
PBSC harvest. Intervention: Donors were randomly assigned to 
receive 400btg/m^2 of G-CSF (filgrastim) subcutaneously once 
daily or in two-divided doses every 12 hours on 3 consecutive 
d~ys. PBSC was collected by leukapheresis u ing COBE Spectra 
on day 4. Main Outcome Measures: The primary endpoint of this 
study was CD34 positive cell dose per kg of donor's body weight 
collected by leukapheresis on day 4. Additional endpoints were 
total nucleated cell (TNC) counts in the leukapheresis products, 
total pain burden experienced by donor measured with area under 
curve (AUC) of visual analogue scale (VAS), and total dose of 
analgesic drugs. Safety endpoints: Incidence and severity of 
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adverse events. Main Results: The number of CD34+ cells in the 
leukapheresis products were similar in the two groups: the geo- 
metric mean number of CD34+ cells was 1.73 x 10^6/kg in the 
once-daily group and 2.08 x 10^6/kg in the divided-dose group 
(P=.0.37). The geometric mean number of TNCs in the products 
was 6.43 x 10^8/kg in the once-daily group and 6.35 x 10A8/kg in 
the twice-daily group (P=0.87). Although the median total doses 
of analgesic drug were similar in both groups (6.35mg/kg vs 
7.69mg/kg acetoaminophen, P=0.79), the donors in the once-dally 
group experienced significantly less pain than twice-daily group 
(median AUS of VAS; 21.5 vs 52.5 ram*days, P=0.043). The inci- 
dences and severities of adverse vents other than pain were simi- 
lar in both groups. Conclusions: In comparison with two-divided 
dose regimen, once daily injection of 400btg/m^2 of G-CSF is 
equally effective for allogeneic PBSC nmbilization and associated 
with less pain. Taldng into account of donor's convenience, once- 
daily regimen is preferable to twice-daily regimen. 
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IN VITRO PRIMING AND EXPANSION OF CMV-SPECIFIC THI AND 
TCI T CELLS FROM NAIVE CORD BLOOD LYMPHOCYTES BY AUTOL- 
OGOUS DENDRITIC CELLS 
S:abolcs, P., Ma1~i, L.; Reese, 3/14 I~;rtzbe'rg, ft.; Par~e, K. Dulee Uni- 
versity, Pediatric BMT Progr, zm, Dm'taam, NC. 
BACKGROUND: Adoptive transfer of CMV specific cytoto~c T 
cells (CTL) expanded in vitro from donor memory cells have reduced 
CMV disease in the allogeneic BMT setting. However, dais approach 
has not been feasible in the unrelated cord blood transplant (uUCBT) 
setting as cord blood contains naive, unprimed T ceils. YVe developed 
an in vitro protocol to prime and expand CMV-specific CTL from 
cord blood. METHODS: Monocytes from 6 UCB units were cul- 
tured with GM-CSF/IL-4 for 6 days to generate immature Des 
(Mo/DCs). Autologous UCB lymphocytes were primed either with 
CMV-lysate-pulsed Mo/DCs (CMV+) or as negative controls 
unpulsed (CNIV-) or sham Iysate loaded Mo/DCs. Prior to priming 
CMV +/- loaded immature DC received 12h maturation signals 
(TNFc~+PGE2) inducing expression of CDS0, CD86 and HLA mol- 
ecules. For restimulation and expansion of CTL cultures DC were 
generated from CD34+ cells cultured in SCF/Flt-3L/GM-CSF/IL- 
4 for 14 ~ 21days and GM-CSF/IL-4 for 6days. DCs and responder 
lymphocytes were cultured in the presence of low dose IL-2 
(10IU/ml), IL-7, and IL-12 to skew the priming and expansion 
towards ThI and Tcl cells. CTL cultures were -stimulated weeldy 
for 5~ 7 weeks. After the 4th week CD3+ T cells were tested weeHy 
by ic FACS analysis for CMV-specific IFNy, TNFc( secretion. 
CMV-specific cytotoxicity was tested by LDH release assay on 
CMV+, CMV or sham lysate loaded autologous Mo/DC. 
RESULTS: CMV+ cultures expanded significantly more (3.5 ~ 13.39 
tbld) than CMV- cultures (0.65 ~ 7.8 fold) despite identical cytokine 
milieu. There was a preferential expansion of CD45RA-/RO+ 'mem- 
ory' T cells in CMV+ cultures compared to CMV- cultures (CMV+: 
66~86% of CD3+ versus CMV-: 30 ~ 46% of CD3+. CMV-specific 
interferon gamma produchag T cells were 4.7 ~ 35.3 % (mean: 16.1%) 
in CMV+ cultures and 0 ~ 2% (mean 0.5%) of CD3+ in CMV-cul 
rares respectively (p=0.025) witla bo h CD4+ (Thl) and CD8+ (TcI) 
T cells contributing. CMV-specific CTtOto.-dcity at10:1 E:T ratio was 
31 ~ 48 % from CMV+ cultures and 10~ 13% from CMV- or sham 
lysate cultures. CONCLUSION: This dataset is the first to our 
knowledge to demonstrate the generation of CMV-specific CTLs 
that were primed and expanded in vitro from naive umbilical cord 
lymphocytes. This approach may lead to effective clinical strategies 
against CMV infection in the uUCB transplantation setting. 
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UPREGULATION OF THE EXPRESSION OF MOLECULES INVOLVED IN 
ALLORECOGNITION: IMPLICATIONS FOR POTENTIATING THE MIXED 
LYMPHOCYTE REACTION PRIOR TO SELECTIVE ALLOREACTIVE T 
CELL DEPLETION 
Davies, ff.K.; Koh, M.B.; Prentice, H.; Lowdell, 3/I.FV. Depa;~tment of 
Haematology, Royal Free Hospital, London, United Kingdom. 
Various mechanisms ofselective depletion of alloreactive T cells in 
haematopoietic stem ceil (HSC)grafts have been described: all 
depend upon the stimulation of donor alloreactive cells byrecipient 
cells in a unidirectional mixed lymphocyte reaction (MLR). In the 
HLA identical donor setting, stimulation of alloreactive donor cells in 
a standard MLR often fails to occur: in this setting amodification of 
the MLR with cytoldne pre-treatment of stimulator cells has been 
described. We investigated the effect of two strategies designed to 
potentiate the MLR on expression of cell surface molecules impor- 
tant in allostimulation. The expression of adhesion molecules 
(CD1 la, CD54(ICAM I)), co-stimulatury molecules (CD80 and 
CD86) and HLA class I and Class II molecules were measured by 
flow cytometry after stimulation of monocytes and T cells with 
TNF-alpha, IL4 and/or gamma-interferon f r 24 and 48 hours. Sim- 
ilar observations were made of T cells stinmlated with immobilized 
nfitogenic OKT3 +/- agonistic anti-CD28. The e~pression of CD178 
(Fas ligand) in these cells was also determined at 24 and 48 hours. 
Effective upregulation of molecules involved in allorecognition 
occurred with all three cytokines on monocytes and with g-IFN and 
TNF a on T cells. Use of immobilised OKT3 caused much greater 
increases in eNaression of similar molecules on T ceils and an increase 
in the proportion of T ceils expressing FAS ligand. The addition of 
anti-CD28 to OKT3 had no additional benefit in upregulation of 
these molecules. Results are summarised below (NT=Not Tested). 
Both strategies may enhance alloantigen presentation i  the HLA 
identical situation and facilitate the activation (and subsequent 
removal) of alloreactive cells in HSC grafts. The increase in the pro- 
portion ofT ceils expressing FAS ligand seen with OKT3 stimulation 
may enhance FAS-mediated apoptosis of alloreactive cells. We are 
currendy investigating the use of both techniques in modifications of
the MLR as part of our selective allodepletion research programme. 
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TIME-TEMPERATURE STUDY OF CELL SURVIVAL IN BONE MARROW 
(BM) AND BLOOD HEMATOPOIETIC PROGENITOR CELL (HPC) GRAFTS 
Rosenthal, H.S/; Miller, ft.:; Hicks, AI.1; Weisdo~f, D/; Waller, E.K/ 
i. Emmy University, Atlanta, GA; 2. U~iversity of Mimzesota, 3/lin- 
neapolis, 3/[~ 
Background: Standard practice in BM and blood HPC trans- 
plants facilitated by the NMDP is to ship BM HPC grafts at 
room temperature and blood HPC grafts at 4°C. There is lim- 
ited information regarding the effect of storage conditions on 
the content of cell subsets in the graft. We undertook a 
prospective study of the effect of time and temperature on the 
content of viable CD34+ cells, T-cell, B-cell, NK cells and den- 
dritic cell subsets in blood and BM HPC grafts. Method: Small 
aliquots of blood (N=4) and BM (N=5) HPC grafts from 
patients harvested at two transplant centers were obtained from 
quality control samples discarded from the processing laborato 
ries. The number of viable nucleated cells was determined by 
fluorescent microscopy following staining with ethidium bro- 
mide and acridine orange and storage for 24, 48 or 72 hours at 
4°C or RT. The content of CD34+ cells, T-cells, B-cells, NK 
cells and dendritic cell subsets was determined using flow 
cytometry and propidium iodide to electronically exclude non- 
viable cells. Results: BM grafts had better overall cell viability 
during storage than bIood HPC grafts at both temperatures. 
The median number of viable CD34+ cells in BM HPC grafts 
was stable at 4°C and RT during 48 hours storage then 
declined to 50% and 29% of the initial values, respectively, 
after 72 hours. In contrast, there was a steady decline in the 
numbers of viable CD34+ cells in blood HPC grafts throughout 
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